Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

November 28, 2025

Primary Completion Date

September 28, 2027

Study Completion Date

September 4, 2028

Conditions

Myasthenia Gravis

Interventions

DRUG

Nipocalimab

Nipocalimab will be administered intravenously.

DRUG

Efgartigimod

Efgartigimod will be administered intravenously.

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY